Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
British Journal of Haematology
|
February 25, 2015
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death
Yuko Mishima, Loredana Santo, Homare Eda, et al.
Blood Advances
|
April 30, 2025
Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma
Elizabeth O'Donnell, Thais Gift, Zaid Yousif, et al.
Haematologica
|
August 23, 2023
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
Paul G Richardson, Brian G Durie, Laura Rosiñol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 26, 2018
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia
Steven P Treon, Joshua Gustine, Kirsten Meid, et al.
Journal of Translational Autoimmunity
|
February 8, 2021
Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison
Lorenzo Montali, Andrea Gragnano, Massimo Miglioretti, et al.
Nature
|
December 2, 2016
Genomic evolution and chemoresistance in germ-cell tumours
Amaro Taylor-Weiner, Travis Zack, Elizabeth O'Donnell, et al.
Psycho-Oncology
|
July 18, 2025
Psychosocial and NF-κB Activity Effects of the Stress Management and Resiliency Training: Relaxation Response Resiliency Program (SMART-3RP) on Patients With MGUS and Smoldering Multiple Myeloma: A Randomized Waitlist Control Trial
Lucy Finkelstein-Fox, John W Denninger, Leah E Walsh, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 3, 2024
Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone
Omar Nadeem, Michelle P Aranha, Robert Redd, et al.
Leukemia
|
September 17, 2021
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
Jorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.
Nature Communications
|
January 3, 2025
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
Omar Nadeem, Michelle P Aranha, Robert Redd, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
British Journal of Haematology
|
February 25, 2015
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death
Yuko Mishima, Loredana Santo, Homare Eda, et al.
Blood Advances
|
April 30, 2025
Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma
Elizabeth O'Donnell, Thais Gift, Zaid Yousif, et al.
Haematologica
|
August 23, 2023
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
Paul G Richardson, Brian G Durie, Laura Rosiñol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 26, 2018
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia
Steven P Treon, Joshua Gustine, Kirsten Meid, et al.
Journal of Translational Autoimmunity
|
February 8, 2021
Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison
Lorenzo Montali, Andrea Gragnano, Massimo Miglioretti, et al.
Nature
|
December 2, 2016
Genomic evolution and chemoresistance in germ-cell tumours
Amaro Taylor-Weiner, Travis Zack, Elizabeth O'Donnell, et al.
Psycho-Oncology
|
July 18, 2025
Psychosocial and NF-κB Activity Effects of the Stress Management and Resiliency Training: Relaxation Response Resiliency Program (SMART-3RP) on Patients With MGUS and Smoldering Multiple Myeloma: A Randomized Waitlist Control Trial
Lucy Finkelstein-Fox, John W Denninger, Leah E Walsh, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 3, 2024
Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone
Omar Nadeem, Michelle P Aranha, Robert Redd, et al.
Leukemia
|
September 17, 2021
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
Jorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.
Nature Communications
|
January 3, 2025
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
Omar Nadeem, Michelle P Aranha, Robert Redd, et al.
Page
of 5